Ojas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.25 Cr
as on 19-06-2024
- Paid Up Capital ₹ 9.35 M
as on 19-06-2024
- Company Age 31 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit 94.71%
(FY 2021)
- Ebitda 94.71%
(FY 2021)
- Net Worth -0.36%
(FY 2021)
- Total Assets 0.02%
(FY 2021)
About Ojas Pharmaceuticals
The Corporate was formerly known as Sangfroid Industries Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.25 Cr and a paid-up capital of Rs 9.35 M, as per Ministry of Corporate Affairs (MCA) records.
Adisesha Jagarapu, Shoba Jagarapu, and Shabarish Jagarapu serve as directors at the Company.
- CIN/LLPIN
U24230TG1993PLC016508
- Company No.
016508
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Nov 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Mahabub Nagar, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ojas Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shabarish Jagarapu  | Additional Director | 18-Jul-2008 | Current |
| Adisesha Jagarapu | Additional Director | 22-Jun-2020 | Current |
| Shoba Jagarapu | Additional Director | 16-Jul-2021 | Current |
Financial Performance and Corporate Structure Insights of Ojas Pharmaceuticals.
Ojas Pharmaceuticals Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 94.71% increase in profit. The company's net worth dipped by a decrease of 0.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ojas Pharmaceuticals?
In 2021, Ojas Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Degradable Polymer Technologies Private LimitedActive 14 years 2 monthsShoba Jagarapu and Shabarish Jagarapu are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ojas Pharmaceuticals?
Unlock and access historical data on people associated with Ojas Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ojas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ojas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
